Commercials APIs & APIs Under Development

RUSAN PHARMA PRIVATE LIMITED, an Indian pharmaceutical company specializing in addiction treatment and pain management, announced that its Active Pharmaceutical Ingredient (API) facility in Ankleshwar, Gujarat, received Good Manufacturing Practice (GMP) approval from the USFDA on May 29, 2024, following a rigorous inspection. This approval marks a significant milestone, enabling Rusan to expand into the US API market, particularly for niche APIs like Eflornithine and Nalmefene, while planning to add more APIs to its portfolio. Rusan Pharma’s Managing Director, Dr. Kunal Saxena, emphasized the company’s commitment to quality and global expansion. The USFDA approval complements Rusan's existing GMP certifications from Health Canada, the EU, and Brazil’s ANVISA, and aligns with the company’s vision to be a leader in addiction treatment and pain management.